UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

12 Apr 2024

Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY[®]▼ (romosozumab) can help to close the treatment gap in osteoporosis

Read More
12 Apr 2024

UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting

Read More
11 Apr 2024

Transparency notification FMR LLC

Read More
5 Apr 2024

Acquisition of own shares

Read More
4 Apr 2024

FDA Accepts Supplemental Biologics License Applications for BIMZELX[®] (bimekizumab-bkzx) for Moderate to Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Read More
29 Mar 2024

Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees

Read More

Stay up-to-date on the latest news and information from UCB